Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) traded up 0.9% during mid-day trading on Thursday. The company traded as high as $1.10 and last traded at $1.08. 104,870 shares were traded during mid-day trading, a decline of 28% from the average session volume of 146,325 shares. The stock had previously closed at $1.07.
Actinium Pharmaceuticals Stock Performance
The stock’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.08. The stock has a market capitalization of $34.59 million, a P/E ratio of -0.79 and a beta of 0.26.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Compass Financial Management LLC acquired a new stake in shares of Actinium Pharmaceuticals in the second quarter valued at about $588,000. BlackRock Inc. bought a new stake in Actinium Pharmaceuticals in the second quarter valued at approximately $388,000. Finally, Renaissance Technologies LLC boosted its holdings in Actinium Pharmaceuticals by 20.7% in the first quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares during the last quarter. 27.50% of the stock is owned by institutional investors and hedge funds.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing targeted radiotherapies for the treatment of hematologic malignancies. Its platform uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying diseased cells while reducing damage to healthy tissue.
The company’s leading product candidate is Iomab-B, also known as iostamab-I-131 or apamistamab, an investigational targeted conditioning agent designed to prepare patients with relapsed or refractory acute myeloid leukemia for hematopoietic stem cell transplantation.
Read More
- Five stocks we like better than Actinium Pharmaceuticals
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
- Schneider Just Paid Up for PTC—Is the SaaSpocalypse Overdone?
- Delta Air Lines Faces a Fuel Crisis—But There’s a Silver Lining
- Is Synopsys Back from the Dead? EDA Leader Inks Deals With Amazon and OpenAI
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
